Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study

European Journal of Cancer

Volumn 51, Issue 4, 2015, Pages 473-481

  Di Bartolomeo, Maria ^a   Ciarlo, Andrea ^b   Bertolini, Alessandro ^c   Barni, Sandro ^d   Verusio, Claudio ^e   Aitini, Enrico ^f   Pietrantonio, Filippo ^a   Iacovelli, Roberto ^a   Dotti, Katia Fiorella ^a   Maggi, Claudia ^a   Perrone, Federica ^a   Bajetta, Emilio ^g  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MISERICORDIA E DOLCE HOSPITAL   (Italy)

^c Transfusion Medicine and Haematology Department   (Italy)

^d AO Treviglio   (Italy)

^e AO Saronno ^*  (Italy)

^f Medical Oncology Department   (Italy)

^g Policlinico   (Italy)

Author keywords

Bevacizumab; Capecitabine; Colorectal cancer; Triplet chemotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE PAIN; CANCER GROWTH; COLORECTAL CANCER; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG ACTIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; MIDDLE AGED; MORTALITY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 84925012061     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.12.020     Document Type: Article

References (30)

1. American Cancer Society Cancer facts & figures 2014 2014 American Cancer Society Atlanta
2. S. Bengmark, and L. Hafstrom The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy Cancer 23 1969 198 202
3. A. Grothey, D. Sargent, and R.M. Goldberg Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 22 2004 1209 1214
4. C. Tournigand, T. André, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237
5. A.P. Guglielmi, and A.F. Sobrero Second-line therapy for advanced colorectal cancer Gastrointest Cancer Res 1 2007 57 63
6. A. Falcone, S. Ricci, and I. Brunetti Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J Clin Oncol 25 2007 1670 1676
7. J. Souglakos, N. Androulakis, and K. Syrigos FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) Br J Cancer 94 2006 798 805
8. E. Bajetta, L. Celio, and E. Ferrario Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer Ann Oncol 18 2007 1810 1816
9. Bevacizumab summary of product characteristics. Available at: < http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125085s0169lbl.pdf > (last entry 09.04.14).
10. G. Masi, F. Loupakis, and L. Salvatore Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial Lancet Oncol 11 2010 845 852
11. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
12. M. Di Bartolomeo, F. Pietrantonio, F. Perrone on behalf of Italian Trials in Medical Oncology (ITMO) Group Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT Target Oncol 9 2014 155 162
13. F. Molinari, L. Felicioni, and M. Buscarino Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer Clin Cancer Res 17 2011 4901 4914
14. National cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) v. 3. Available at: < http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf >.
15. R. Simon Optimal two-stage design for Phase II clinical trials Control Clin Trials 10 1989 1 10
16. L. Rubbia-Brandt, E. Giostra, and C. Brezault Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery Ann Oncol 18 2007 299 304
17. R. Iacovelli, F. Pietrantonio, and A. Palazzo Incidence and relative risk of grade 3 and 4 diarrhea in patients treated with capecitabine or 5-fluorouracil. A meta-analysis of published trials Br J Clin Pharmacol 24 2014 [Epub ahead of print]
18. L.J. Oostendorp, P.F. Stalmeier, and P.C. Pasker-de Jong Review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer Anticancer Drugs 21 2010 749 758
19. C.H. Köhne, J. De Greve, and J.T. Hartmann Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015 Ann Oncol 19 2008 920 926
20. C.S. Fuchs, J. Marshall, and E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study J Clin Oncol 25 2007 4779 4786
21. E. Van Cutsem, B. Nordlinger, A. Cervantes ESMO Guidelines Working Group Advanced colorectal cancer: ESMO clinical practice guidelines for treatment Ann Oncol 21 suppl. 5 2010 93 97
22. F.S. Falvella, S. Cheli, and C. Maggi Prospective observational study for DPYD and UGT1A1 deficiency-associated toxicity in patients with metastatic colorectal cancer (mCRC) receiving triplet chemotherapy with capecitabine, irinotecan and oxaliplatin (COI) Ann Oncol 25 suppl. 4 2014 [Abstr 532P]
23. J.L. Fischel, P. Rostagno, and P. Formento Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines Br J Cancer 84 2001 579 585
24. T. Gruenberger, J.A. Bridgewater, and I. Chau Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: resectability and safety in OLIVIA J Clin Oncol 24 suppl. 2013 [abstr 3619]
25. F. Loupakis, C. Cremolini, and L. Salvatore FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer Eur J Cancer 50 1 2014 57 63
26. F. Loupakis, C. Cremolini, and G. Masi Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer N Engl J Med 371 2014 1609 1618
27. D. Koeberle, D.C. Betticher, and R. Von Moos Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III noninferiority trial (SAKK 41/06) J Clin Oncol 31 suppl. 2013 [abstr 3503]
28. M. Koopman, L.H. Simkens, and A.M. May Final results and subgroup analyses of the phase 3 CAIRO3 study: maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC) J Clin Oncol 32 suppl. 5 2014 [abstr 3504]
29. D. Arnold, U. Graeven, and C.A. Lerchenmuller Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): a phase III non-inferiority trial (AIO KRK 0207) J Clin Oncol 32 suppl. 5 2014 [abstr 3503]
30. E. Díaz-Rubio, F. Pietrantonio, and F. de Braud Continuing single-agent bevacizumab as maintenance therapy after induction XELOX(or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer Oncologist 17 2012 1426 1428